How much does a box of Upatinib cost?

Upadacitinib is a selective Janus kinase (JAK) inhibitor that regulates intracellular signaling mainly by inhibiting JAK1. JAK1Plays an important role in a variety of inflammatory and immune responses, so upadatinib was developed to treat a variety of immune-mediated inflammatory diseases.

Upatinib is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of about 2,000 yuan. Please consult the local hospital pharmacy for specific prices and medical insurance reimbursement. Upadatinib is relatively cheap in the form of generic drugs abroad, mainly in Laos and Bangladesh. The price is around six to seven hundred yuan, and its ingredients are basically the same as those of the domestic original drug.

Currently, upadatinib has been approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and moderate to severe atopic dermatitis (AD< span>), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and other diseases. For these diseases, upadacitinib is often used in patients who have responded poorly to conventional treatments or biologics. By inhibiting JAK1, it reduces the release of pro-inflammatory cytokines, relieves patients' inflammatory symptoms, and improves quality of life.

The common dosage form of upadacitinib is oral tablets, and the recommended dosage varies depending on the indications. For rheumatoid arthritis, 15 mg once daily is generally recommended, but the dose may be adjusted based on the patient's condition and tolerance. During medication, patients need to have liver function and blood routine monitoring regularly to avoid potential adverse reactions.

Common side effects of upadacitinib include upper respiratory tract infection, headache, nausea, etc. It should be noted that it may increase the risk of serious infections, thrombotic events, and certain malignancies, so patients should be carefully assessed for infection risk and cardiovascular status. The efficacy and safety of upadatinib have been verified in multiple clinical trials, showing that it can significantly improve the condition of patients, especially when other drugs are ineffective or poorly tolerated, making it an important treatment option.